Register Now
Overview:
Hidradenitis suppurativa is a chronic inflammatory skin disease with a prevalence of 0.40% (95% CI, 0.26%-0.63%) in Australia, Scandinavia, the U.S., and Western Europe.1 It is a progressive disease which negatively impacts the quality of life for those who are diagnosed with it, particularly due to the painful nodular lesions that can abscess and scar.2 Additionally, the diagnosis rate of hidradenitis suppurativa may be lower than the actual number of cases due to patients not seeking treatment, delaying care or missed diagnoses. All these issues can contribute to progression of disease or mortality.
The CME-certified, live Dermatology Summit will be available as a virtual satellite symposium. It aims to fill the clinical gaps by providing education to improve the diagnosis of hidradenitis suppurativa, improve disease treatment and enhance overall knowledge about treatment guidelines. Emphasis will also be made on the patient experience and disease burden, as well as management strategies. Overall, this program has the aim of improving the quality of life for patients with hidradenitis suppurativa.
References:
1. Jfri A et al. JAMA Dermatol. 2021 Aug; 157(8): 1–8.
2. Calao M et al. PLoS One. 2018; 13(7): e0200683.
3. PER program Agenda and Grant proposal
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Describe the characteristic features of HS and the challenges that result from associated psychological and medical comorbidities
- Assess the importance of referring to a specialist for diagnosis, further assessment and care
- Construct multifaceted and multidisciplinary treatment strategies for patients with HS which are informed by available evidence and individual patient needs
- Develop individualized management plans for patients with HS which incorporate aspects of the patient journey
Target Audience:
This educational activity is directed toward dermatologists. Primary care physicians and other health care professionals interested in the treatment of patients with hidradenitis suppurativa will be invited to participate.
Satellite Symposium: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa Friday, July 14, 2023 8:00 PM to 9:15 PM EST |
||
8:00 PM |
Faculty introductions, Program Overview, and Pretest Assessment |
Afsaneh Alavi, MD |
8:10 PM |
Overview of Disease Manifestations, Pathophysiology, and Disease Burden |
Afsaneh Alavi, MD |
8:20 PM |
Diagnosis and Referral Strategies |
Steven R Cohen, MD, MPH |
8:35 PM |
Current and Emerging Therapies |
Afsaneh Alavi, MD |
8:50 PM |
Individualizing Clinical Management |
Steven R Cohen, MD, MPH |
9:05 PM |
Program Summary and Posttest Assessment |
Steven R Cohen, MD, MPH |
Afsaneh Alavi, M.D.
Dermatologist
Mayo Clinic
Rochester, MN
Steven R. Cohen, MD
Chief, Dermatology
Montefiore
Bronx, NY
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.